When evaluating the developments and complications of a marginally viable premature infant, physicians and parents must work together to decide on treatment that is in the infant’s best interest.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
A case that illustrates how Western medicine's body or mind approach to diagnosis and treatment can differ from that of many patients from non-Western cultures.